HAVCR2 and neoplasm: It is possible that anti-tumor synergy produced by anti-PD-L1 in combination with anti-LAG-3 or anti-TIM-3 antibodies may be a less toxic alternative to anti-PD-L1 in combination with anti-CTLA4 antibodies.